Research programme: RLIP76 protein - Terapio
Latest Information Update: 28 Aug 2018
At a glance
- Originator University of Texas at Arlington
- Developer Terapio Corporation
- Class Membrane transport proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute radiation syndrome; Skin disorders
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for preclinical development in Acute-radiation-syndrome in USA (PO)
- 28 Aug 2018 No recent reports of development identified for preclinical development in Skin-disorders in USA (Topical)
- 05 Aug 2016 Peclinical development is ongoing in USA